PURPOSE: To describe concentration versus time profiles of capecitabine and its metabolites 5'-DFUR, 5'-DFCR and 5-FU, depending on tablet formulation and on frequent and/or relevant genetic polymorphisms of cytidine deaminase, dihydropyrimidine dehydrogenase, thymidylate synthase and methylenetetrahydrofolate reductase (MTHFR). METHODS: In 46 cancer patients on chronic capecitabine treatment, who voluntarily participated in the study, individual therapeutic doses were replaced on four consecutive mornings by the study medication. The appropriate number of 500 mg test (T) or reference (R) capecitabine tablets was given in randomly allocated sequences TRTR or RTRT (replicate design). Average bioavailability was assessed by ANOVA. RESULTS: Thirty female and 16 male patients suffering from gastrointestinal or breast cancer (mean age 53.4 years; mean dose 1739 mg) were included. The T/R ratios for AUC0-t(last) and C max were 96.7 % (98 % CI 90.7-103.2 %) and 87.2 % (98 % CI 74.9-101.5 %), respectively. Within-subject variability for AUC0-t(last) and C max (coefficient of variation for R) was 16.5 and 30.2 %, respectively. Similar results were seen for all metabolites. No serious adverse events occurred. For the MTHFR C677T (rs1801133) genotype, an increasing number of 677C alleles showed borderline correlation with an increasing elimination half-life of capecitabine (p = 0.043). CONCLUSIONS: The extent of absorption was similar for T and R, but the rate of absorption was slightly lower for T. While such differences are not considered as clinically relevant, formal bioequivalence criteria were missed. A possible, probably indirect role of the MTHFR genotype in pharmacokinetics of capecitabine and/or 5-FU should be investigated in further studies.

Department of Pharmacology University of Cologne Cologne Germany

Department of Pharmacology University of Cologne Cologne Germany Clinical Trials Centre Cologne Medical Faculty University of Cologne Gleueler Str 269 50935 Cologne Germany

M A R C O GmbH and Co KG Düsseldorf Germany

Quinta Analytica S r o Prague Czech Republic

Synthon BV Nijmegen The Netherlands

000      

00000naa a2200000 a 4500

001      

bmc16010013

003      

CZ-PrNML

005      

20160412123653.0

007      

ta

008      

160408s2015 gw f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s00280-015-2840-6 $2 doi

024    7_

$a 10.1007/s00280-015-2840-6 $2 doi

035    __

$a (PubMed)26242222

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a gw

100    1_

$a Queckenberg, Christian $u Department of Pharmacology, University of Cologne, Cologne, Germany. christian.queckenberg@uk-koeln.de. Clinical Trials Centre Cologne, Medical Faculty, University of Cologne, Gleueler Str. 269, 50935, Cologne, Germany. christian.queckenberg@uk-koeln.de.

245    10

$a Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations / $c C. Queckenberg, V. Erlinghagen, BC. Baken, SH. Van Os, M. Wargenau, V. Kubeš, R. Peroutka, V. Novotný, U. Fuhr,

520    9_

$a PURPOSE: To describe concentration versus time profiles of capecitabine and its metabolites 5'-DFUR, 5'-DFCR and 5-FU, depending on tablet formulation and on frequent and/or relevant genetic polymorphisms of cytidine deaminase, dihydropyrimidine dehydrogenase, thymidylate synthase and methylenetetrahydrofolate reductase (MTHFR). METHODS: In 46 cancer patients on chronic capecitabine treatment, who voluntarily participated in the study, individual therapeutic doses were replaced on four consecutive mornings by the study medication. The appropriate number of 500 mg test (T) or reference (R) capecitabine tablets was given in randomly allocated sequences TRTR or RTRT (replicate design). Average bioavailability was assessed by ANOVA. RESULTS: Thirty female and 16 male patients suffering from gastrointestinal or breast cancer (mean age 53.4 years; mean dose 1739 mg) were included. The T/R ratios for AUC0-t(last) and C max were 96.7 % (98 % CI 90.7-103.2 %) and 87.2 % (98 % CI 74.9-101.5 %), respectively. Within-subject variability for AUC0-t(last) and C max (coefficient of variation for R) was 16.5 and 30.2 %, respectively. Similar results were seen for all metabolites. No serious adverse events occurred. For the MTHFR C677T (rs1801133) genotype, an increasing number of 677C alleles showed borderline correlation with an increasing elimination half-life of capecitabine (p = 0.043). CONCLUSIONS: The extent of absorption was similar for T and R, but the rate of absorption was slightly lower for T. While such differences are not considered as clinically relevant, formal bioequivalence criteria were missed. A possible, probably indirect role of the MTHFR genotype in pharmacokinetics of capecitabine and/or 5-FU should be investigated in further studies.

650    _2

$a metabolická aktivace $x genetika $7 D065767

650    _2

$a aplikace orální $7 D000284

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a alely $7 D000483

650    _2

$a antimetabolity antitumorózní $x aplikace a dávkování $x farmakokinetika $7 D000964

650    _2

$a plocha pod křivkou $7 D019540

650    _2

$a capecitabinum $x aplikace a dávkování $x farmakokinetika $7 D000069287

650    _2

$a karboxylesterasa $x metabolismus $7 D043182

650    _2

$a cytidindeaminasa $x genetika $x metabolismus $7 D003564

650    _2

$a deoxycytidin $x analogy a deriváty $x metabolismus $7 D003841

650    _2

$a dihydrouracildehydrogenasa (NADP) $x genetika $x metabolismus $7 D042943

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a floxuridin $x metabolismus $7 D005467

650    _2

$a fluorouracil $x metabolismus $7 D005472

650    _2

$a genotyp $7 D005838

650    _2

$a lidé $7 D006801

650    _2

$a játra $x enzymologie $7 D008099

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a methylentetrahydrofolátreduktasa (NADPH2) $x genetika $x metabolismus $7 D042965

650    _2

$a lidé středního věku $7 D008875

650    _2

$a nádorové proteiny $x metabolismus $7 D009363

650    _2

$a jednonukleotidový polymorfismus $7 D020641

650    _2

$a prekurzory léčiv $x aplikace a dávkování $x farmakokinetika $7 D011355

650    _2

$a tablety $7 D013607

650    _2

$a terapeutická ekvivalence $7 D013810

650    _2

$a thymidinfosforylasa $x metabolismus $7 D013939

650    _2

$a thymidylátsynthasa $x genetika $x metabolismus $7 D013940

655    _2

$a srovnávací studie $7 D003160

655    _2

$a časopisecké články $7 D016428

655    _2

$a multicentrická studie $7 D016448

655    _2

$a randomizované kontrolované studie $7 D016449

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Erlinghagen, V $u Department of Pharmacology, University of Cologne, Cologne, Germany.

700    1_

$a Baken, B C M $u Synthon BV, Nijmegen, The Netherlands.

700    1_

$a Van Os, S H G $u Synthon BV, Nijmegen, The Netherlands.

700    1_

$a Wargenau, M $u M.A.R.C.O. GmbH & Co. KG, Düsseldorf, Germany.

700    1_

$a Kubeš, V $u Quinta-Analytica S.r.o., Prague, Czech Republic.

700    1_

$a Peroutka, R $u Quinta-Analytica S.r.o., Prague, Czech Republic.

700    1_

$a Novotný, V $u Quinta-Analytica S.r.o., Prague, Czech Republic.

700    1_

$a Fuhr, U $u Department of Pharmacology, University of Cologne, Cologne, Germany.

773    0_

$w MED00001040 $t Cancer chemotherapy and pharmacology $x 1432-0843 $g Roč. 76, č. 5 (2015), s. 1081-91

856    41

$u https://pubmed.ncbi.nlm.nih.gov/26242222 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20160408 $b ABA008

991    __

$a 20160412123737 $b ABA008

999    __

$a ok $b bmc $g 1113442 $s 934381

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 76 $c 5 $d 1081-91 $e 20150805 $i 1432-0843 $m Cancer chemotherapy and pharmacology $n Cancer Chemother Pharmacol $x MED00001040

LZP    __

$a Pubmed-20160408